This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Sep 2011

Catalent & Toyobo Ink Deal for Japanese Market

US-based Catalent Pharma Solutions and Toyobo Biologics in Japan have formed a partnership to co-promote Catalent’s proprietary GPEx technology in the Japanese market.

Catalent Pharma Solutions, the Somerset, NJ-based drug and biologic development services provider, and Toyobo Biologics, Inc. (TBI), a biologics supplier and contract provider of large scale clinical and commercial bioreactors in Japan, have signed a partnership agreement to co-promote Catalent’s proprietary GPEx technology in the Japanese market.

 

GPEx technology is used for mammalian cell line development. It creates stable, high expression cell lines "that will speed biologics drug development to clinic in one-third the time of traditional approaches," according to a Catalent statement. GPEx uses a retrovector technology to ensures stable transduction of targeted cells, approaching 100% efficiency.

 

TBI owns and operates a GMP manufacturing plant with bioreactors ranging from 1

Related News